Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC daily Stock Chart
AstraZeneca PLC
Index- P/E39.58 EPS (ttm)0.97 Insider Own0.50% Shs Outstand2.53B Perf Week-1.11%
Market Cap96.87B Forward P/E21.76 EPS next Y1.76 Insider Trans0.00% Shs Float2.52B Perf Month-7.66%
Income2.45B PEG3.00 EPS next Q0.78 Inst Own18.30% Short Float0.84% Perf Quarter1.97%
Sales21.45B P/S4.52 EPS this Y-13.40% Inst Trans7.49% Short Ratio4.65 Perf Half Y6.37%
Book/sh4.71 P/B8.12 EPS next Y3.84% ROA3.90% Target Price43.04 Perf Year15.39%
Cash/sh1.67 P/C22.91 EPS next 5Y13.20% ROE18.50% 52W Range32.69 - 41.78 Perf YTD10.17%
Dividend1.40 P/FCF- EPS past 5Y-13.50% ROI13.30% 52W High-8.49% Beta0.52
Dividend %3.66% Quick Ratio0.70 Sales past 5Y-4.30% Gross Margin79.50% 52W Low16.95% ATR0.74
Employees61100 Current Ratio0.90 Sales Q/Q-14.30% Oper. Margin14.00% RSI (14)38.36 Volatility1.47% 1.55%
OptionableYes Debt/Eq1.75 EPS Q/Q-37.20% Profit Margin11.30% Rel Volume0.63 Prev Close38.35
ShortableYes LT Debt/Eq1.54 EarningsNov 08 BMO Payout141.60% Avg Volume4.57M Price38.23
Recom1.60 SMA20-3.41% SMA50-2.56% SMA2002.55% Volume2,882,080 Change-0.31%
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Apr-05-17Downgrade UBS Buy → Neutral
Mar-09-17Initiated Liberum Buy
Dec-09-16Upgrade Leerink Partners Mkt Perform → Outperform
Dec-18-18 08:21PM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
05:18PM  Why a kidney disease drug approval in China is just the start for this S.F. company American City Business Journals
11:19AM  [$$] Big Pharma Wins Drug Approval in China Ahead of West for First Time The Wall Street Journal
09:30AM  BMY vs. AZN: Which Stock Should Value Investors Buy Now? Zacks
06:24AM  China first to approve AstraZeneca, FibroGen anaemia drug Reuters
Dec-17-18 03:22PM  Merck to Acquire Europe's Antelliq Group for $2.4 Billion Zacks
07:00AM  Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases PR Newswire
Dec-14-18 08:19AM  Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus Zacks
Dec-13-18 12:15PM  Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi GlobeNewswire
03:17AM  Edited Transcript of AZN.L earnings conference call or presentation 26-Jul-18 11:30am GMT Thomson Reuters StreetEvents
Dec-12-18 01:07AM  Here is What Hedge Funds Think About AstraZeneca plc (AZN) Insider Monkey
Dec-11-18 12:42PM  Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate Benzinga
10:26AM  Moderna Stock Ushers In the Next Wave of Biotech InvestorPlace
07:19AM  Can Moderna Stock Recover From Its Initial Setback? Motley Fool
Dec-08-18 08:09PM  Is Bristol Myers Squibb Co. (BMY) A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-07-18 04:11PM  New Biotech IPO Dropped a Unicorn-Sized Value on Its First Day Bloomberg
02:55AM  AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study Reuters
Dec-05-18 10:18PM  Here's Why Agenus Stock Popped 51.6% in November Motley Fool
09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
07:48AM  GlaxoSmithKline Capital Inc. -- Moody's changes GSK's outlook to negative; affirms A2 ratings Moody's
07:00AM  Today's Research Reports on Trending Tickers: Eli Lilly and Company and AstraZeneca ACCESSWIRE
12:00AM  [$$] Repeat offender companies warned of fresh investor onslaught Financial Times
Dec-04-18 08:27AM  Glaxo to Buy Zejula Maker TESARO for $5.1B, Stock Down 8% Zacks
08:06AM  TESARO Shares Rally on Glaxo's $5.1 Billion Buyout Offer Zacks
Dec-03-18 01:45PM  New Long-Term Data on CALQUENCE Presented at ASH 2018 Business Wire
06:41AM  [$$] Stocks to watch: GSK, RPC, Stobart, Ted Baker, Bodycote, Tesaro Financial Times
Nov-29-18 04:05PM  Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech Investor's Business Daily
02:30AM  Biocartis partners with AstraZeneca on lung cancer diagnostics Reuters
01:39AM  Biocartis partners with AstraZeneca on lung cancer diagnostics Reuters
01:01AM  Biocartis Group NV: Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results GlobeNewswire
12:17AM  AstraZeneca PLC (LON:AZN): The Best Of Both Worlds Simply Wall St.
Nov-28-18 08:16AM  3 Top Dividend Stocks to Buy Right Now Motley Fool
Nov-27-18 07:51PM  [$$] Drugmakers Gain More Access to China, but at a Price The Wall Street Journal
10:39AM  Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease Zacks
07:00AM  AstraZeneca Presents Clinical Research Advances for Blood Cancer Patients at 2018 American Society of Hematology Annual Meeting Business Wire
Nov-26-18 09:23AM  The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca Zacks
Nov-23-18 08:58AM  Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs Zacks
07:18AM  Read This Before You Buy AstraZeneca PLC (LON:AZN) Because Of Its P/E Ratio Simply Wall St.
Nov-22-18 09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
Nov-21-18 09:02AM  Clovis' (CLVS) Rubraca Gets Another US Patent, Shares Up Zacks
08:58AM  TESARO Shares Rally on Rumors of Potential Acquisition Offer Zacks
08:16AM  Can Deal Interest Help Tesaro Recover? Motley Fool
Nov-20-18 08:12AM  Pfizer's Bavencio Phase III Study for Ovarian Cancer Fails Zacks
07:00AM  Today's Research Reports on Trending Tickers: AstraZeneca and AbbVie ACCESSWIRE
Nov-19-18 02:33PM  Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta Zacks
09:49AM  AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down Zacks
Nov-16-18 09:39AM  Stocks Slide At Open; This Dow Jones Name Bucks Chip Sell Off Investor's Business Daily
08:35AM  Pharma Stock Roundup: FDA Updates on MRK, AZN's Cancer Drugs, Bayer's Q3 Earnings Zacks
08:31AM  AstraZeneca Shows It Can Still Take Some Knocks Bloomberg
08:09AM  Is AstraZeneca PLC (LON:AZN) Excessively Paying Its CEO? Simply Wall St.
03:08AM  AstraZenecas Lung Cancer Trial Fails to Meet Main Goal Bloomberg
02:43AM  [$$] AstraZeneca Mystic lung cancer trial fails to deliver results Financial Times
Nov-14-18 03:22PM  AstraZeneca to Sell US Rights of Lung Infection Drug to Sobi Zacks
10:28AM  Tesaro, Clovis Rally on FDA Priority Review for Lynparza sNDA Zacks
05:45AM  AstraZeneca (AZN): Are Hedge Funds Right to be Bearish? Insider Monkey
Nov-13-18 04:45PM  This Recent Big Pharma Breakout Spiked Again On A $1.5 Billion Deal Investor's Business Daily
01:41PM  AstraZeneca's Lynparza Gets Priority Review in 1st Line Use Zacks
10:47AM  $1.5B deal: AstraZeneca sells U.S. rights to respiratory medicine American City Business Journals
05:05AM  AstraZeneca Keeps Pruning Drugs in $1.5 Billion Sale to Sobi Bloomberg
04:36AM  [$$] European Corporate Roundup The Wall Street Journal
03:33AM  Sobi buys rights to AstraZeneca infant drug for $1.5 bln upfront Reuters
02:35AM  AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront Reuters
Nov-12-18 06:55AM  US FDA Accepts Regulatory Submission For LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-mutated Advanced Ovarian Cancer and Grants Priority Review Business Wire
Nov-10-18 04:45PM  FARXIGA Significantly Reduced Hospitalization for Heart Failure or CV Death in a Broad Patient Population with Type 2 Diabetes in the Landmark DECLARE-TIMI 58 Trial Business Wire
04:45PM  AstraZeneca's diabetes drug curbs heart failure, kidney risks Reuters
04:45AM  [$$] AstraZeneca diabetes drug cuts complications Financial Times
Nov-09-18 07:31AM  Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Zacks
07:00AM  Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb ACCESSWIRE
01:32AM  [$$] Opinion today: Europes plan for Donald Trump Financial Times
Nov-08-18 04:14PM  AstraZeneca Breaks Out As CEO Predicts 'Sustained Growth' Streak Investor's Business Daily
03:37PM  Edited Transcript of AZN.L earnings conference call or presentation 8-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
12:20PM  AstraZeneca lifts FTSE as U.S. midterm rally fades Reuters
11:35AM  AstraZeneca chief says the US drugs market is under pressure and changes are coming CNBC
10:38AM  AstraZeneca sees years of growth as drug sales turn corner Reuters
10:38AM  AstraZeneca's (AZN) Q3 Earnings Beat, New Drugs Drive Sales Zacks
10:36AM  Astrazeneca: 3Q Earnings Snapshot Associated Press
10:33AM  AstraZeneca sees years of growth as drug sales turn corner Reuters
06:24AM  [$$] AstraZeneca 3Q Sales Increased on New Drug Performance The Wall Street Journal
04:42AM  [$$] European Corporate Roundup The Wall Street Journal
03:18AM  AstraZeneca has finally delivered its four-year objective... CNBC Videos
02:26AM  AstraZeneca returns to sales growth, led by cancer medicines CNBC
02:14AM  AstraZeneca returns to sales growth, led by cancer medicines Reuters
12:01AM  [$$] AstraZeneca: back from the abyss Financial Times
Nov-07-18 11:09PM  [$$] AstraZeneca shares surge as new drugs spark hope of growth Financial Times
04:00PM  Immunomedics Expands Clinical Collaboration With Astrazeneca to Include Metastatic Non-Small Cell Lung Cancer GlobeNewswire
01:29PM  Astrazeneca Q3 Earnings Preview Benzinga
Nov-06-18 05:48PM  Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference Call Transcript Motley Fool
09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
09:12AM  Cheplapharm Arzneimittel GmbH -- Moody's affirms Cheplapharm's B1 CFR, assigns B1 to term loan add-on, stable outlook Moody's
07:00AM  Today's Research Reports on Trending Tickers: AbbVie and AstraZeneca ACCESSWIRE
04:44AM  [$$] European Corporate Roundup The Wall Street Journal
03:18AM  [$$] AstraZeneca sells trio of respiratory drugs for $350m Financial Times
03:03AM  AstraZeneca sells older asthma, rhinitis drugs for $350 million Reuters
02:44AM  AstraZeneca sells older asthma, rhinitis drugs for $350 mln Reuters
Nov-02-18 08:09AM  Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus Zacks
Nov-01-18 01:59PM  European businesses demand urgent Brexit deal after meeting May Reuters
07:00AM  The Landmark DECLARE-TIMI 58 Cardiovascular Outcomes Trial of FARXIGA in Patients with Type 2 Diabetes to Be Featured at AHA 2018 Business Wire
Oct-30-18 05:31PM  AstraZeneca sells some rights to Nexium, Vimovo to Grunenthal Reuters
04:53AM  [$$] European Corporate Roundup The Wall Street Journal
03:30AM  [$$] AstraZeneca to Sell Drugs Rights for $815M The Wall Street Journal
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 22Buy5.00600,0003,000,0003,004,554Oct 24 04:16 PM
ASTRAZENECA PLC10% OwnerSep 28Buy15.00246,6663,699,9902,164,855Oct 02 09:35 PM